A new study highlights age, allergies, smoking, and history of angioedema as non-genetic risk factors for ACEi/ARB-induced ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

Telling patients how many extra days they’ll be free from an event can help with shared decision-making, experts say.

IgA nephropathy (IgAN) is an autoimmune disorder that affects the kidneys by impairing the filtration function of the small ...

Rates of arrhythmic events and death remained common in patients indicated for implantable cardioverter defibrillator or ...

BOSTON — Sparsentan, a first-in-class, oral dual endothelin-angiotensin receptor antagonist, shows significant benefit in reducing proteinuria in the difficult-to-manage focal segmental ...

FILSPARI is the only Dual Endothelin Angiotensin Receptor Antagonist (DEARA), a non-immunosuppressive therapy for the treatment of IgAN approved in Europe and is currently available in Germany, ...

FILSPARI is the only Dual Endothelin Angiotensin Receptor Antagonist (DEARA), a non-immunosuppressive therapy for the treatment of IgAN approved in Europe and is currently available in Germany, ...

Lorundrostat, a selective aldosterone synthase inhibitor, significantly reduced 24-hour systolic blood pressure in individuals with uncontrolled and treatment-resistant hypertension, according to ...

High-dose angiotensin-converting-enzyme inhibitors, however, are at least as effective as high-dose angiotensin blockers and less expensive. Angiotensin-converting-enzyme inhibition is thus the ...

In the past, doctors used several types of medicines to treat high blood pressure. These included water pills called ...